News Category
Tonix Pharmaceuticals will report third-quarter 2026 financial results on Nov. 9, 2026, providing investors with a key update on its commercial launch...
The American Heart Association's selection of five finalists for its 2026 Health Tech Competition highlights a strategic effort to accelerate adoption...
NanoViricides has initiated a Phase IIA trial of NV-387 Oral Gummies for Ebola Bundibugyo virus in the DRC, a key step toward validating its broad-spe...
Quantum BioPharma's agreement with Thermo Fisher's clinical research business moves its lead multiple sclerosis drug candidate, Lucid-MS, into a Phase...
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher Scientific's clinical research business to initiate a Phase 2 trial of Luci...
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher's clinical research business to initiate a Phase 2 trial of Lucid-MS, a nov...
XORTX Therapeutics is advancing XORLO, a proprietary oxypurinol formulation, toward an FDA new drug application as gout cases are expected to rise sig...
Quantum BioPharma's Study Start-Up Agreement with Thermo Fisher Scientific marks a crucial step toward launching a Phase 2 trial of Lucid-MS, a potent...
NanoViricides will present at the NIBA 153rd Investment Conference on October 7, 2026, highlighting its broad-spectrum antiviral NV-387, which is in P...
Quantum BioPharma's Study Start-Up Agreement with Thermo Fisher for its Lucid-MS Phase 2 trial marks a critical step toward developing a first-in-clas...
The CDSCO's authorization of Okogen's EMERALD Phase 1/2 study for Treyegen (OKG-0303) pushes forward a novel single therapy designed to treat both vir...
NanoViricides has provided an update on its Phase II clinical trial of NV-387 Oral Gummies for Ebola, highlighting the potential of an oral antiviral ...
In vitro ADME studies are critical for early assessment of drug candidates, helping to avoid late-stage clinical trial failures and streamline develop...
A new study reveals that individual bacterial strains in the microbiome influence the risk of developing sepsis, meningitis, or pneumonia from air pol...
Peptide Wholesale Supply has extended HPLC peptide testing and batch traceability to bulk orders of BPC-157, Semaglutide, and Tirzepatide, enhancing a...
Experts emphasize that asking about clinical trials at the first appointment can open doors to promising new treatments and improved quality of life f...
GeoVax has entered an agreement with CEPI to use its Centralised Laboratory Network for independent testing of GEO-MVA, which could help diversify glo...
Tevard Biosciences and collaborators published preclinical research demonstrating that engineered suppressor tRNAs can restore full-length dystrophin ...
Creative Biolabs has expanded its functionalized lipid-based delivery system development to help researchers address stability, targeting, and control...
BioCorRx Inc. has appointed Richard J. Baum, former Acting Director of the White House Office of National Drug Control Policy, to its Strategic Adviso...
Regentis Biomaterials reported positive progress in its Phase III GelrinC trial and received European approval for a manufacturing process that boosts...
Quantum BioPharma's FDA clearance to launch a Phase 2 trial of Lucid-MS, a first-in-class myelin-protecting drug, could revolutionize multiple scleros...
Regentis Biomaterials is developing GelrinC, an off-the-shelf hydrogel implant designed to regenerate knee cartilage, offering a potential alternative...
VERAXA Biotech's appointment of Dr. Christoph Erkel as chief scientific officer strengthens its scientific leadership as it advances its BiTAC® platfo...
Quantum BioPharma's FDA clearance for a Phase 2 trial of Lucid-MS marks the first time a drug designed to protect and rebuild myelin will be tested in...
Quantum BioPharma's Lucid-MS, a first-in-class PAD2 inhibitor, has received FDA clearance to begin a Phase 2 trial in multiple sclerosis, marking a si...
Quantum BioPharma's Lucid-MS, a first-in-class myelin-protecting and potentially regenerating therapy, receives FDA clearance for a Phase 2 trial, mar...
Helus Pharma's CEO Michael Halstead will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference, providing a pl...
Onco-Innovations' CMO discussed the company's lead drug candidate ONC010, which targets the DNA repair enzyme PNKP and has shown promising preclinical...
Quantum BioPharma's FDA clearance for its Lucid-MS IND allows a phase 2 trial in multiple sclerosis, potentially offering a first-in-class treatment t...
Recurrent UTIs in women are often misdiagnosed and undertreated due to outdated diagnostic methods, highlighting an urgent need for advanced testing t...
Silo Pharma's participation in the IPAC-RS 2026 Nasal Innovation Forum underscores the progress of its intranasal PTSD therapeutic, SPC-15, with stabi...
Quantum BioPharma's FDA clearance for Lucid-MS Phase 2 trial marks a pivotal step toward a novel therapy that could repair myelin, potentially transfo...
Quantum BioPharma's Lucid-MS, a first-in-class myelin-protective candidate for multiple sclerosis, has received FDA clearance for a Phase 2 trial and ...
GeoVax supports the new Gavi-funded global mpox vaccine stockpile, emphasizing the need for diversified supply and highlighting its GEO-MVA candidate'...
VERAXA Biotech's appointment of seasoned financial leader Raju Willener as CFO signals a strategic move to strengthen its capital position and advance...
Scinai Immunotherapeutics strategically pivots its R&D to prioritize its NanoAb platform and CDMO business following the termination of its PinCell ag...
Onco-Innovations has made significant progress in manufacturing, IND-enabling activities, and financing to advance its lead oncology candidate ONC010 ...
Quantum BioPharma's FDA clearance for a phase 2 trial of Lucid-MS, a first-in-class drug targeting myelin repair, marks a significant step toward addr...
Researchers at Washington University School of Medicine have advanced laser interstitial thermal therapy (LITT) as a less invasive brain cancer treatm...
Ocumetics Technology Corp. has initiated patient recruitment for Group Two of its human clinical study, marking a pivotal step in evaluating the safet...
Quantum BioPharma's FDA clearance to test Lucid-MS, a first-in-class remyelinating agent, in a Phase 2 trial marks a pivotal step toward a treatment t...
NanoViricides has registered its Phase II Ebola trial in the DRC, marking a significant step in developing an oral antiviral treatment against Ebola v...
Quantum BioPharma has received FDA clearance to begin a Phase 2 trial of its novel multiple sclerosis drug candidate Lucid-MS, marking a significant s...
Quantum BioPharma's FDA clearance to proceed with a Phase 2 trial of Lucid-MS, a novel demyelination-targeting candidate, marks a pivotal step in MS t...
Quantum BioPharma's FDA clearance to begin a Phase 2 trial of Lucid-MS, a first-in-class drug targeting demyelination in multiple sclerosis, marks a s...
Tonix Pharmaceuticals' promotion of Thomas Englese to Chief Commercial Officer underscores its strategic focus on commercial execution and the expansi...
A study of 5,617 colorectal cancer patients reveals that the timing of brain metastasis development significantly impacts survival, offering crucial p...
